| UHC UMR Medical and Drug | Entyvio® (Vedolizumab) – Commercial Medical Benefit Drug Policy | 2025-07-01 |
| UHC UMR Medical and Drug | Exondys 51® (Eteplirsen) – Commercial Medical Benefit Drug Policy | 2025-07-01 |
| UHC UMR Medical and Drug | Gonadotropin Releasing Hormone Analogs – Commercial Medical Benefit Drug Policy | 2025-07-01 |
| UHC UMR Medical and Drug | Korsuva® (Difelikefalin) – Commercial Medical Benefit Drug Policy | 2025-07-01 |
| UHC UMR Medical and Drug | Niktimvo™ (Axatilimab-Csfr) – Commercial Medical Benefit Drug Policy | 2025-07-01 |
| UHC UMR Medical and Drug | Saphnelo® (Anifrolumab-Fnia) – Commercial Medical Benefit Drug Policy | 2025-07-01 |
| UHC UMR Medical and Drug | Scenesse® (Afamelanotide) – Commercial Medical Benefit Drug Policy | 2025-07-01 |
| UHC UMR Medical and Drug | Spevigo® (Spesolimab-Sbzo) – Commercial Medical Benefit Drug Policy | 2025-07-01 |
| UHC UMR Medical and Drug | Viltepso® (Viltolarsen) – Commercial Medical Benefit Drug Policy | 2025-07-01 |
| UHC UMR Medical and Drug | Vyondys 53® (Golodirsen) – Commercial Medical Benefit Drug Policy | 2025-07-01 |